Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of GSK3389404 in Chronic Hepatitis B
CTR20180509Phase 2Completed
- Sponsor
- GSK
- Start
- May 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GSK3389404 in Chronic Hepatitis B (CHB), sponsored by GSK. Started May 2018; status: completed.
02
Drugs
GSK3389404
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20180509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180509.